Peripheral Neuropathy Causes and Treatment

Introduction

Peripheral neuropathy encompasses a heterogeneous group of disorders characterized by damage to the peripheral nervous system, leading to sensory, motor, or autonomic dysfunction. The clinical spectrum ranges from mild paresthesia to profound motor weakness and autonomic instability. Over the past century, advances in neurophysiology and imaging have refined diagnostic criteria, while therapeutic strategies have evolved from symptomatic symptom control to targeted disease-modifying interventions. The relevance of peripheral neuropathy to pharmacology is underscored by the high prevalence of drug-induced neuropathies, the necessity of dose adjustments in patients with comorbid neuropathic conditions, and the role of pharmacologic agents in mitigating pain and slowing neurodegeneration. Understanding the pathogenesis and therapeutic landscape is therefore essential for medical and pharmacy practitioners seeking to optimize patient outcomes.

Learning objectives for this chapter include:

• Describing the epidemiology and classification of peripheral neuropathies.
• Elucidating the cellular and molecular mechanisms underlying common etiologies.
• Interpreting neurophysiologic testing and imaging findings in peripheral neuropathy.
• Evaluating pharmacologic and non-pharmacologic therapeutic options, with emphasis on evidence-based practice.
• Applying clinical reasoning to case scenarios involving drug-induced and systemic neuropathies.

Fundamental Principles

Core Concepts and Definitions

Peripheral neuropathy refers to any disorder affecting the peripheral nerves outside the central nervous system. The International Neuropathy Consortium defines it as a dysfunction of one or more peripheral nerves resulting from structural or functional abnormalities. Symptoms typically follow a length-dependent pattern, with distal extremities being most affected, although focal or generalized presentations occur. Classifications are broadly divided into demyelinating, axonal, and mixed forms, determined by the primary pathological substrate. Demyelination implicates the myelin sheath, leading to slowed conduction velocities, whereas axonal loss results in reduced amplitude of compound muscle action potentials and sensory nerve action potentials. Mixed neuropathies exhibit both features.

Etiologic categories include metabolic, nutritional, infectious, hereditary, toxic, and idiopathic causes. Each category presents with distinct clinical and electrophysiologic signatures, informing diagnostic strategies and therapeutic choices. The term “polyneuropathy” describes involvement of multiple nerves, whereas “mononeuropathy” indicates isolated nerve damage.

Theoretical Foundations

The pathophysiology of peripheral neuropathy is multifactorial. Metabolic insults, such as hyperglycemia in diabetes mellitus, lead to microvascular compromise, oxidative stress, and accumulation of advanced glycation end products, ultimately damaging axons. Nutritional deficiencies, notably of B vitamins, disrupt axonal transport and myelin synthesis. In infectious neuropathies, immune-mediated mechanisms or direct viral invasion compromise nerve integrity. Toxic agents exert neurotoxicity through mitochondrial dysfunction, disruption of microtubules, or generation of reactive oxygen species. Genetic mutations affecting ion channels, mitochondrial DNA, or structural proteins underlie hereditary neuropathies, often presenting in a hereditary sensory and autonomic neuropathy (HSAN) or Charcot-Marie-Tooth disease spectrum.

The “dying-back” phenomenon, where distal axonal segments degenerate first, is a hallmark of many axonal neuropathies. This progressive degeneration is accompanied by Wallerian degeneration, Schwann cell proliferation, and eventual loss of myelin integrity. The interplay between neuronal injury and the immune system is increasingly recognized, particularly in immune-mediated neuropathies such as Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy (CIDP).

Key Terminology

• Conduction velocity (CV): speed at which an action potential travels along a nerve; reduced in demyelinating neuropathies.
• Amplitude: size of the action potential; diminished in axonal neuropathies.
• Distal motor latency (DML): time from stimulus to muscle response; prolonged in demyelination.
• Mononeuropathy: isolated nerve injury.
• Polyneuropathy: simultaneous involvement of multiple nerves.
• Axonal degeneration: loss of axonal integrity leading to functional loss.
• Demyelination: loss or disruption of the myelin sheath.
• Wallerian degeneration: process of axonal breakdown distal to injury.

Detailed Explanation

Etiologic Spectrum and Mechanisms

Metabolic neuropathies constitute the most prevalent category, with diabetes mellitus being the leading cause. Chronic hyperglycemia induces endothelial dysfunction, reduced Na⁺/K⁺-ATPase activity, and accumulation of sorbitol within Schwann cells, culminating in demyelination and axonal loss. Oxidative stress further exacerbates neuronal injury by damaging mitochondria and compromising ATP production, a critical energy source for axonal transport.

In nutritional deficiencies, vitamin B12 deficiency impairs myelin formation through disruption of methylmalonyl-CoA mutase, leading to subacute combined degeneration. Thiamine deficiency, often seen in chronic alcoholism, impairs transketolase activity, reducing nucleotide synthesis and leading to axonal degeneration. Zinc and copper deficiencies, though less frequent, also contribute to neuropathic manifestations through impaired enzymatic functions and oxidative imbalance.

Infectious neuropathies encompass a spectrum from acute post-infectious demyelinating processes such as Guillain-Barré syndrome to chronic infections like HIV-associated neuropathy. The pathogenic mechanisms vary from molecular mimicry triggering immune-mediated demyelination to direct viral cytopathic effects on Schwann cells. Cytokine release and oxidative stress are common denominators.

Toxic neuropathies arise from exposure to chemotherapeutic agents (e.g., cisplatin, vincristine), heavy metals (e.g., lead, arsenic), and environmental toxins (e.g., organophosphates). These agents damage axons by disrupting microtubule dynamics, inhibiting axonal transport, or inducing mitochondrial dysfunction. For instance, cisplatin forms DNA adducts in dorsal root ganglion neurons, triggering apoptosis and demyelination.

Hereditary neuropathies involve mutations in genes encoding for peripheral nerve proteins. Charcot-Marie-Tooth disease type 1A, for example, results from PMP22 gene duplication, leading to myelin protein overexpression and subsequent demyelination. Other subtypes involve mutations in MFN2, causing mitochondrial fusion defects and axonal degeneration. The clinical presentation is often early-onset, progressive, and may involve a combination of sensory, motor, and autonomic deficits.

Electrophysiologic and Imaging Models

Electrodiagnostic studies (EDX) provide quantitative data on nerve function. The sum of conduction velocity (CV) and amplitude (Amp) yields a composite measure reflecting both demyelination and axonal loss. In demyelinating neuropathies, CV is reduced while Amp may remain relatively preserved. Conversely, axonal neuropathies show significant Amp reduction with relatively normal CV. The ratio of CV to Amp (CV/Amp) can be used to differentiate between the two patterns, with a lower ratio suggesting predominant demyelination.

Imaging modalities such as high-resolution ultrasound and magnetic resonance neurography (MRN) visualize nerve morphology. Ultrasound can detect nerve enlargement, hypoechogenicity, and abnormal echogenicity, while MRN provides detailed visualization of nerve roots, trunks, and peripheral nerves, allowing assessment of signal intensity changes indicative of edema or demyelination. The apparent diffusion coefficient (ADC) values obtained from diffusion-weighted imaging may reflect microstructural changes, with increased ADC suggesting demyelination and decreased ADC indicating axonal loss.

Mathematical Relationships and Pharmacokinetic Considerations

Pharmacologic interventions targeting peripheral neuropathy often rely on dose titration based on patient weight and renal function. For example, the standard oral dosing of gabapentin involves an initial dose of 300 mg three times daily, with increments of 300 mg three times daily up to a maximum of 1800 mg daily. Dose adjustments are typically guided by trough plasma concentrations, with target levels of 100–200 µg/mL for neuropathic pain control. Renal clearance (Cl) influences drug elimination, with C_max inversely proportional to Cl (C_max ∝ 1/Cl). The area under the concentration–time curve (AUC) is calculated as Dose ÷ Cl, offering a metric for systemic exposure.

In patients receiving neurotoxic chemotherapeutic agents, cumulative dose thresholds are critical. For example, cisplatin-induced neuropathy risk increases markedly beyond a cumulative dose of 400 mg/m², with a dose–response relationship approximated by AUC = Dose ÷ Clearance. Monitoring blood levels and adjusting schedules can mitigate neurotoxicity, underscoring the importance of pharmacokinetic monitoring in clinical practice.

Factors Influencing Disease Progression

Age, glycemic control, nutritional status, genetic predisposition, and concurrent comorbidities such as renal impairment influence neuropathy progression. Hyperglycemia accelerates nerve damage through polyol pathway activation, whereas hypoglycemia can precipitate acute neuropathic episodes. Nutrient adequacy modulates myelin synthesis and axonal repair. Renal insufficiency hampers drug clearance, increasing exposure to neurotoxic agents, and may exacerbate uremic neuropathy. Genetic variants in detoxification enzymes (e.g., CYP2D6) affect individual susceptibility to drug-induced neuropathy.

Clinical Significance

Relevance to Drug Therapy

Peripheral neuropathy presents a significant challenge in pharmacotherapy, often necessitating dose reductions or discontinuation of essential medications. For instance, the neurotoxic potential of platinum-based chemotherapies requires vigilant monitoring and dose adjustments. Antiretroviral agents such as stavudine and didanosine have historically contributed to neuropathic complications, prompting their withdrawal or substitution with safer alternatives. Additionally, certain antibiotics (e.g., aminoglycosides) and antiepileptics (e.g., phenytoin) can precipitate neuropathic manifestations, necessitating therapeutic drug monitoring.

Pharmacologic management of neuropathic pain emphasizes agents that modulate neuronal excitability and neurotransmitter pathways. First-line agents include duloxetine, a serotonin–norepinephrine reuptake inhibitor (SNRI), and pregabalin, a ligand of the α2δ subunit of voltage-gated calcium channels. These medications reduce ectopic discharges and central sensitization. Opioids, while sometimes employed, carry risks of tolerance and hyperalgesia, limiting their long-term utility. Non-pharmacologic strategies such as transcutaneous electrical nerve stimulation (TENS) and cognitive-behavioral therapy complement drug therapy, offering multimodal pain control.

Practical Applications

In clinical practice, a structured approach to neuropathy involves patient history, neurologic examination, and targeted investigations. Electrophysiologic studies are pivotal for distinguishing demyelinating from axonal processes, guiding therapeutic decisions. For example, a patient with diabetic sensorimotor polyneuropathy may benefit from tight glycemic control and duloxetine therapy, whereas a patient with chemotherapy-induced neuropathy may require dose reduction and adjunctive agents such as vitamin B complex or low-dose amifostine.

Drug selection often balances efficacy, safety, and patient-specific factors. In elderly patients with polypharmacy, the risk of drug–drug interactions and renal clearance limitations necessitates careful medication review. Polyneuropathy secondary to nutritional deficiencies may respond to high-dose vitamin supplementation, highlighting the importance of addressing reversible causes before resorting to symptomatic therapy.

Clinical Applications/Examples

Case Scenario 1: Diabetic Sensorimotor Polyneuropathy

A 58-year-old man with type 2 diabetes presents with burning pain in both feet, decreased vibration sense, and ankle reflex loss. HbA1c is 9.2%, indicating suboptimal glycemic control. Nerve conduction studies reveal reduced amplitudes and mildly slowed conduction velocities, consistent with axonal polyneuropathy. Management includes initiation of duloxetine 30 mg daily, titrated to 60 mg daily as tolerated, alongside intensive glycemic control targeting HbA1c ≤7%. Regular monitoring of renal function is advised, given duloxetine’s hepatic metabolism and potential for hepatic impairment. Non-pharmacologic measures such as foot care education and physical therapy are recommended to prevent ulceration and maintain function.

Case Scenario 2: Chemotherapy-Induced Neuropathy

A 45-year-old woman undergoing adjuvant cisplatin therapy for ovarian carcinoma develops numbness and paresthesia in her toes after receiving a cumulative dose of 400 mg/m². Electrophysiologic evaluation shows reduced sensory nerve action potential amplitudes. To mitigate further neurotoxicity, the oncology team reduces the cisplatin dose by 20% and adds a neuroprotective agent, such as vitamin E at 400 IU daily, though evidence remains inconclusive. Additionally, gabapentin is initiated at 300 mg three times daily to address neuropathic pain. The patient’s renal function is monitored closely, and dose adjustments are made accordingly.

Case Scenario 3: Vitamin B12 Deficiency Neuropathy

A 70-year-old woman presents with gait instability, numbness in the lower extremities, and decreased proprioception. Serum vitamin B12 levels are 150 pmol/L (normal range 140–700 pmol/L). High-dose intramuscular cyanocobalamin 1000 µg weekly is administered for 4 weeks, followed by maintenance dosing of 500 µg daily. Repeat neurologic examination after 6 weeks shows improvement in proprioception and reduced pain. The patient is advised to maintain adequate dietary intake of B12-rich foods and to monitor levels annually.

Problem-Solving Approach

• Identify etiology: metabolic, nutritional, toxic, hereditary, or idiopathic.
• Confirm diagnosis with appropriate investigations (e.g., blood tests, EDX, imaging).
• Eliminate reversible causes (e.g., vitamin deficiencies, drug toxicity).
• Implement disease-modifying therapy (e.g., glycemic control, dose adjustment).
• Provide symptomatic pain management with evidence-based agents and multimodal strategies.
• Monitor therapeutic response and adjust treatment accordingly.

Summary/Key Points

• Peripheral neuropathy is a broad spectrum of disorders affecting sensory, motor, or autonomic fibers, with etiologies ranging from metabolic to toxic to hereditary.
• Electrophysiologic studies differentiate demyelinating from axonal neuropathies, guiding therapeutic decisions.
• Metabolic causes, particularly diabetes, predominate and involve oxidative stress, microvascular compromise, and mitochondrial dysfunction.
• Toxic neuropathies are common in oncology; cumulative dose thresholds and pharmacokinetic monitoring are essential for prevention.
• Nutritional deficiencies, especially of vitamin B12 and thiamine, represent reversible causes requiring supplementation.
• First-line pharmacologic agents for neuropathic pain include duloxetine and pregabalin; opioids are reserved for refractory cases.
• Multimodal management incorporating glycemic control, dietary optimization, and non-pharmacologic therapies yields the best outcomes.
• Regular monitoring of renal and hepatic function is crucial when prescribing neurotoxic or neuroprotective agents.

References

1. Ropper AH, Samuels MA, Klein JP, Prasad S. Adams and Victor's Principles of Neurology. 12th ed. New York: McGraw-Hill Education; 2023.
2. Bennett PN, Brown MJ, Sharma P. Clinical Pharmacology. 12th ed. Edinburgh: Elsevier; 2019.
3. Waller DG, Sampson AP. Medical Pharmacology and Therapeutics. 6th ed. Edinburgh: Elsevier; 2022.
4. Feather A, Randall D, Waterhouse M. Kumar and Clark's Clinical Medicine. 10th ed. London: Elsevier; 2020.
5. Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. 21st ed. New York: McGraw-Hill Education; 2022.
6. Ralston SH, Penman ID, Strachan MWJ, Hobson RP. Davidson's Principles and Practice of Medicine. 24th ed. Edinburgh: Elsevier; 2022.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.